This study is currently not recruiting participants.

A Double-blind Placebo Controlled Randomized Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson

Investigational Medication for Parkinson's Disease

Not Recruiting
30 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this research study is to test the safety and the effect of the study drug, rasagiline, on Parkinson

Detailed description of study

The purpose of this research study is to test the safety and the effect of the study drug, rasagiline, on Parkinson

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinson's Disease
  • Age: 30 years - 100 years
  • Gender: All

This study investigates the safety and effects of an investigational medication for Parkinson's disease. Parkinson's disease is a disorder of the central nervous system that affects movement, often including tremors. The study aims to learn more about how the investigational medication can impact the symptoms of Parkinson's disease.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The procedures will include regular assessments to monitor the effects and safety of the treatment.

  • Who can participate: Participants must be diagnosed with Parkinson's disease and be within the age range of 40 to 75 years. Key eligibility factors include stable medication regimens and no significant medical conditions that could interfere with participation.
  • Study details: Participants will receive either the investigational medication or a placebo. The study will involve regular assessments to monitor the effects and safety of the treatment.
Updated on 19 Feb 2024. Study ID: 1105005542 (0911-07)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team